1.435
전일 마감가:
$1.44
열려 있는:
$1.45
하루 거래량:
112.40K
Relative Volume:
0.30
시가총액:
$129.98M
수익:
-
순이익/손실:
$1.60M
주가수익비율:
47.83
EPS:
0.03
순현금흐름:
$-62.91M
1주 성능:
-1.71%
1개월 성능:
-6.21%
6개월 성능:
-14.07%
1년 성능:
-27.53%
Compugen Ltd Stock (CGEN) Company Profile
CGEN을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
CGEN
Compugen Ltd
|
1.435 | 129.98M | 0 | 1.60M | -62.91M | 0.03 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
505.47 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
567.73 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
631.54 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
258.55 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
247.88 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Compugen Ltd Stock (CGEN) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-01-13 | 개시 | Oppenheimer | Outperform |
2022-08-05 | 다운그레이드 | Jefferies | Buy → Hold |
2020-05-26 | 재개 | JMP Securities | Mkt Outperform |
2020-05-13 | 개시 | Stifel | Buy |
2020-05-07 | 개시 | SVB Leerink | Outperform |
2020-04-22 | 개시 | ROTH Capital | Buy |
2020-03-24 | 개시 | SunTrust | Buy |
2020-01-16 | 개시 | Cantor Fitzgerald | Overweight |
2018-03-29 | 개시 | Oppenheimer | Outperform |
2016-02-01 | 재개 | Oppenheimer | Outperform |
2015-10-15 | 개시 | FBR Capital | Outperform |
2015-04-23 | 재개 | Jefferies | Buy |
2015-04-21 | 개시 | Oppenheimer | Outperform |
2014-02-07 | 개시 | MLV & Co | Buy |
2009-12-28 | 재확인 | Cantor Fitzgerald | Buy |
2009-07-29 | 개시 | Cantor Fitzgerald | Buy |
모두보기
Compugen Ltd 주식(CGEN)의 최신 뉴스
Press Release Distribution & PR Platform - ACCESS Newswire
67,041 Shares in Compugen Ltd. (NASDAQ:CGEN) Acquired by Raymond James Financial Inc. - Defense World
Compugen (NASDAQ:CGEN) vs. Quantum Genomics Société Anonyme (OTCMKTS:QNNTF) Financial Review - Defense World
Commonwealth Equity Services LLC Takes Position in Compugen Ltd. (NASDAQ:CGEN) - Defense World
Compugen Ltd. Announces Appointment of Alberto Sessa as Chief Financial Officer - marketscreener.com
Compugen at Stifel Forum: Strategic Insights on Immunotherapy Pipeline By Investing.com - Investing.com South Africa
Compugen at Stifel Forum: Strategic Insights on Immunotherapy Pipeline - Investing.com Australia
Is There An Opportunity With Compugen Ltd.'s (NASDAQ:CGEN) 33% Undervaluation? - simplywall.st
Compugen at Needham Conference: Strategic Immuno-Oncology Insights - Investing.com Australia
Compugen at Needham Conference: Strategic Immuno-Oncology Insights By Investing.com - Investing.com India
Compugen stock touches 52-week low at $1.35 amid market challenges - Investing.com Canada
Compugen stock touches 52-week low at $1.35 amid market challenges By Investing.com - Investing.com South Africa
BeiGene stock slips on trial discontinuation (ONC:NASDAQ) - Seeking Alpha
Compugen at AI Drug Discovery Conference: Strategic Partnerships Drive Progress - Investing.com
Cancer AI Breakthrough: Compugen Takes Center Stage at 3 Elite Healthcare Forums - Stock Titan
Compugen Ltd. (CGEN): Among the Penny Stocks With Huge Upside Potential According to Analysts - MSN
Compugen Ltd. (NASDAQ:CGEN) Shares Acquired by Connor Clark & Lunn Investment Management Ltd. - Defense World
Reviewing Aligos Therapeutics (NASDAQ:ALGS) and Compugen (NASDAQ:CGEN) - Armenian Reporter
Compugen at Leerink’s Global Healthcare Conference: Strategic Insights By Investing.com - Investing.com South Africa
Compugen at Leerink’s Global Healthcare Conference: Strategic Insights - Investing.com
Oppenheimer & Co. Inc. Raises Stock Position in Compugen Ltd. (NASDAQ:CGEN) - Defense World
Earnings call transcript: Compugen Q4 2024 reveals revenue decline By Investing.com - Investing.com Australia
Compugen Ltd. to Host Earnings Call - ACCESS Newswire
Compugen (NASDAQ:CGEN) Rating Lowered to Hold at StockNews.com - Defense World
Rodman & Renshaw maintains $4 price target on Compugen stock By Investing.com - Investing.com Australia
Compugen Ltd. (NASDAQ:CGEN) Q4 2024 Earnings Call Transcript - Insider Monkey
Compugen Ltd (CGEN) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - GuruFocus.com
Compugen’s 2024 Results Highlight Clinical Progress and Financial Stability - TipRanks
Earnings call transcript: Compugen Q4 2024 reveals revenue decline - Investing.com India
Rodman & Renshaw maintains $4 price target on Compugen stock - Investing.com India
Compugen Ltd reports results for the quarter ended December 31Earnings Summary - TradingView
Compugen (CGEN) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Compugen: Q4 Earnings Snapshot - CTPost
Compugen earnings missed by $0.09, revenue fell short of estimates - Investing.com South Africa
Compugen Reports 2024 Financial Results and Clinical Progress - TipRanks
Compugen: Q4 Earnings Snapshot -March 04, 2025 at 07:23 am EST - Marketscreener.com
Compugen Reports Fourth Quarter and Full Year 2024 Results -March 04, 2025 at 07:13 am EST - Marketscreener.com
Compugen reports Q4 EPS (7c) vs. 11c last year - TipRanks
Earnings Flash (CGEN) COMPUGEN LTD. Posts Q4 Loss $-0.07 Per Share -March 04, 2025 at 07:08 am EST - Marketscreener.com
Earnings Flash (CW9) COMPUGEN LTD. Posts Q4 Revenue $1.5M - Marketscreener.com
Earnings Flash (CGEN) COMPUGEN LTD. Posts Q4 Revenue $1.5M -March 04, 2025 at 07:09 am EST - Marketscreener.com
How Compugen's Cancer Immunotherapy Pipeline Is Advancing While Extending Cash Runway to 2027 - StockTitan
Cancer Immunotherapy Pioneer Compugen to Share Insights at Major Healthcare Conference - StockTitan
Compugen to Participate in a Fireside Chat at the 2025 Leerink Partners Global Healthcare Conference - Yahoo Finance
Compugen Ltd (CGEN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):